Id: CBI_2637 | Pages: 269 | Format : PDF | Published : | Author : Consegic Business Intelligence | Category : Healthcare
Bioresorbable Scaffolds Market size is estimated to reach over USD 2,976.49 Million by 2032 from a value of USD 1,644.35 Million in 2024 and is projected to grow by USD 1,741.67 Million in 2025, growing at a CAGR of 7.7% from 2025 to 2032.
Bioresorbable scaffolds are medical devices used in vascular interventions to provide temporary support to blood vessels. These scaffolds gradually dissolve and are absorbed by the body over time. The scaffolds are made from biocompatible materials that break down naturally without the need for surgical removal. Key features include enhanced healing, reduced risk of long-term complications, and elimination of the need for permanent implants.
These scaffolds are utilized in cardiovascular, orthopedic, and other medical treatments. They find applications in hospitals, clinics, and specialized medical centers. These scaffolds offer significant benefits, including improved patient outcomes, minimized long-term treatment risks, and easier recovery processes.
Bioresorbable scaffolds (BRS) are increasingly being utilized in the treatment of cardiovascular diseases, particularly in coronary artery disease. These scaffolds are designed to provide temporary support to the arteries after angioplasty, gradually dissolving over time, unlike permanent metal stents. The primary driver for the bioresorbable scaffolds market growth is the rising trend for more effective and less invasive treatments for cardiovascular conditions. Unlike traditional metal stents, BRS eliminates the need for long-term implantation, reducing the risks of thrombosis and inflammation. The use of these advanced scaffolds offers patients a more natural recovery process, without permanent foreign bodies remaining in the body.
Therefore, the increasing adoption of bioresorbable scaffolds in cardiovascular procedures accelerates bioresorbable scaffolds market demand and trend.
Despite their advantages, bioresorbable scaffolds are considerably more expensive than traditional metal stents. This higher cost is due to the advanced materials and intricate manufacturing processes required to produce these scaffolds. Additionally, the cost of bioresorbable scaffolds may include the need for specialized training for healthcare professionals and increased monitoring to ensure patient safety. These factors contribute to the reluctance of some hospitals and healthcare providers, particularly in developing regions, to adopt bioresorbable scaffolds as a primary treatment.
As a result, the higher cost presents a significant barrier to the widespread adoption of these technologies in the market.
Bioresorbable scaffolds are finding new applications in the field of orthopedics, particularly in bone repair and regeneration. These scaffolds are used to support bone healing by providing temporary structural support, which gradually resorbs as the bone regenerates. With the increasing focus on regenerative medicine, bioresorbable scaffolds hold potential to be integrated into treatments for fractures, spinal injuries, and joint reconstruction. The development of advanced materials for orthopedic applications offers the opportunity to expand the market for bioresorbable scaffolds beyond cardiovascular procedures.
Therefore, as innovations in orthopedic treatments advance, the bioresorbable scaffold market is expected to diversify and grow in this emerging field.
Based on material, the market is segmented into polymeric scaffolds and metallic scaffolds.
The polymeric scaffolds sector accounted for the largest revenue in bioresorbable scaffolds market share in 2024.
The metallic scaffolds sector is anticipated to register the fastest CAGR during the forecast period.
Based on application, the market is segmented into coronary artery disease treatment and peripheral artery disease treatment.
The coronary artery disease treatment sector accounted for the largest revenue in bioresorbable scaffolds market share in 2024.
The peripheral artery disease treatment sector is anticipated to register the fastest CAGR during the forecast period.
Based on end-users, the bioresorbable scaffolds market is segmented into hospitals, cardiac centers, and ambulatory surgical centers.
The hospital sector accounted for the largest revenue share by 43.90% in 2024.
The ambulatory surgical center segment is anticipated to register the fastest CAGR during the forecast period.
The regional segment includes North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
In 2024, North America was valued at USD 545.45 Million and is expected to reach USD 964.68 Million in 2032. In North America, the U.S. accounted for the highest share of 72.25% during the base year of 2024.
North America dominates the bioresorbable scaffolds market due to advanced healthcare infrastructure, high adoption of innovative medical technologies, and strong research and development investments. The United States is a key contributor, supported by its well-established medical device industry and growing trend for minimally invasive procedures. The presence of major players in the region further strengthens the market, while regulatory approvals for new bioresorbable products and reimbursement policies positively influence bioresorbable scaffolds market expansion. Additionally, increasing awareness of the benefits of bioresorbable scaffolds in treating coronary artery diseases and other cardiovascular conditions contributes to market momentum.
In Asia Pacific, the market is experiencing the fastest growth with a CAGR of 8.1% over the forecast period. The Asia-Pacific region is witnessing rapid adoption of bioresorbable scaffolds due to the increasing prevalence of cardiovascular diseases, urbanization, and rising healthcare expenditure. Countries like China, Japan, and India are key players in the market. Japan, in particular, has a well-established healthcare system that supports the adoption of advanced medical devices. However, challenges related to affordability and healthcare access in emerging markets like India and China may hinder market penetration. Nonetheless, growing healthcare investments and favorable government initiatives to improve medical technologies contribute to the region's potential.
Europe holds a significant share of the bioresorbable scaffolds market, driven by strong demand for innovative cardiovascular solutions and the presence of leading medical device manufacturers. Countries like Germany, the United Kingdom, and France are key markets, with healthcare systems that support the adoption of advanced medical technologies. The European market benefits from high research output, clinical trials, and government funding for healthcare innovations. However, variations in reimbursement policies and market access across countries may limit the market's full potential. Continued regulatory approvals and product innovation are expected to shape market dynamics in Europe.
The Middle East and Africa region presents a developing market for bioresorbable scaffolds, with countries like the United Arab Emirates and Saudi Arabia taking the lead in medical advancements. Healthcare infrastructure improvements and growing awareness of cardiovascular diseases contribute to increased demand for advanced medical devices. However, challenges related to healthcare accessibility, affordability, and limited adoption of advanced medical technologies in certain African nations present barriers. In the Middle East, higher disposable incomes and better healthcare access support the demand for bioresorbable scaffolds. Regional investments in healthcare infrastructure are likely to bolster market development.
Latin America is experiencing gradual expansion in the bioresorbable scaffolds market, supported by increasing healthcare investments and rising awareness of cardiovascular diseases. Brazil and Mexico are key players in the region, with improving healthcare infrastructure and rising demand for advanced medical solutions. However, market penetration is hindered by economic disparities and limited access to cutting-edge medical devices in rural areas. Government initiatives to improve healthcare access and ongoing efforts by medical device companies to introduce affordable solutions are expected to enhance market performance in the region.
The Global Bioresorbable Scaffolds Market is highly competitive with major players providing products and services to the national and international markets. Key players are adopting several strategies in research and development (R&D), product innovation, and end-user launches to hold a strong position in the Global Bioresorbable Scaffolds Market. Key players in the Bioresorbable Scaffolds industry include-
Product Launch:
Report Attributes | Report Details |
Study Timeline | 2019-2032 |
Market Size in 2032 | USD 2,976.49 Million |
CAGR (2025-2032) | 7.7% |
By Material |
|
By Application |
|
By End-User |
|
By Region |
|
Key Players |
|
North America | U.S. Canada Mexico |
Europe | U.K. Germany France Spain Italy Russia Benelux Rest of Europe |
APAC | China South Korea Japan India Australia ASEAN Rest of Asia-Pacific |
Middle East and Africa | GCC Turkey South Africa Rest of MEA |
LATAM | Brazil Argentina Chile Rest of LATAM |
Report Coverage |
|
In 2024, the Bioresorbable Scaffolds Market was USD 1,644.35 million.
In 2032, the market size of Bioresorbable Scaffolds Market is expected to reach USD 2,976.49 million.
The material, application, and end-user are the segments covered in this report.
Abbott Laboratories (United States), Boston Scientific Corporation (United States), Medtronic PLC (Ireland), Biotronik (Germany), Terumo Corporation (Japan), Miv Therapeutics (United States), Biotronik SE & Co. KG (Germany), Reva Medical, Inc. (Australia), Shanghai MicroPort Medical (Group) Co., Ltd. (China), S3V Vascular Technologies, LLC (United States) are the major players in the Bioresorbable Scaffolds market.